Metabolic reprogramming is a hallmark of cancer — yet metabolism remains an under-investigated source of biomarkers. By overlaying genome-wide omics data onto the largest reconstruction of the human metabolic network, we identified glycosaminoglycan (GAG) disaccharides as the most deregulated panel of metabolites in cancer. We call their collective profile the GAGome.
Elypta developed MIRAM® GAGome kits — the first standardized, high-throughput kits to profile the human GAGome. The kits use UHPLC-MS/MS to quantify free glycosaminoglycans across the three main classes found in human biofluids — CS,HS, and HA. A single reproducible workflow takes urine or plasma from sample to quantified GAGome, enabling measurements to be run consistently across sites and studies. The kits have advanced across successive generations, with each improving sensitivity, throughput, and analytical quality.
See how the MIRAM® GAGome kits have evolved →
Access MIRAM® for your research →
.svg)
ISO 13485:2016 certified for Design, development and manufacture of in vitro diagnostic test kits and software for the measurement and interpretation of glycosaminoglycans (GAGs) in human biofluids
